Medtox Scientific — Investor Presentation (May 2012)
9 slides from Medtox Scientific's investor presentation, May 24, 2012
Slide 1: Strategy and Historical Performance
2012 Investor Sheet NASDAQ Symbol: MTOX, Strategy: > Profitable growth > Build market share in large markets (relative to our size) by offering high qualit > y products and services, priced competitively and supported by value added services Leverage existing infrastructure and technical expertise t
Slide 2: Drugs-of-Abuse Testing Services
2012 Investor Sheet MEDTOX NASDAQ Symbol: MTOX www.medtox com Drugs-of-Abuse Testing Services Annual Revenue(in millions) 450 40.0 38.7 35.0 30.0 25.0 20.0 15.0 10.0 50 00 2006 2008 2008 2011 Drugs of- Abuse Testing Services > Estimated $750 million market > 2011 revenues © $41.3 million, up 4.3% fr
Slide 3: Clinical and Other Laboratory Services
2012 Investor Sheet MEDTOX NASDAQ Symbol: MTOX www.medtox com Clinical and Other Laboratory Services ‘Annual Revenue in millions) 40.0 34.9 360 30.0 25.0 20.0 150 10.0 50 00 2007 2008 2009 2010 2011 Clinical and Other Laboratory Services > Estimated $50 billion market ° ° Clinical toxicology (refere
Slide 4: Clinical Trial Services
2012 Investor Sheet M E AT x’ NASDAQ Symbol: MTOX www.medtox com Clinical Trial Services ‘Annual Revenue (in millions) 12.0 10.0 8.0 60 4.0 20 00 2006 2007 2009 2010 2011 Clinical Trial Services > Estimated over $1 billion dollar market > Services provided © Central laboratory services © Assay devel
Slide 5: Laboratory Services Revenue and Total Revenue Breakdown
NASDAQ Symbol: MTOX 2012 Investor Sheet MEDIOX wor. medtox com ‘=Drugs-of-Abuse Testing Services Laboratory Services Revenue Cina and Other Laboratory Services 1000 mcincal Tal Sonces cn 00 g mo ¥ oo @ 0 Bho = no 0 ‘oo 00 208 [207 28 208 200 2 [Grge-oF Ruse Tetng Saas 330267 400 360 206 413 [Cncal a
Slide 6: Diagnostic Products Revenue
2012 Investor Sheet NASDAQ Symbol: MTOX MEDTOX: aia Diagnostic Products Revenue ‘Annual Revenue (in millions) 2006 2007 2008 2009 2010 2011 Di Products - Point-of -C Testing for Drugs-of-Abuse Testing > Estimated $400 - $500 million market > 2011 revenues $22.3 million > QI 2012 revenues increased 1
Slide 7: Consolidated Statements of Income
2012 Investor Sheet NASDAQ Symbol: MTOX MEDIOX wor. medtox com MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF INCOME (Gn thousands, except share and per share data) (Unaudited) ‘Three Months Ended ‘Twelve Months Ended December 31, December 31, 201 doo 201 2010 REVENUES Laboratory services: Drugi
Slide 8: Condensed Consolidated Statements of Income
2012 Investor Sheet MEDTOX we oe a MEDTOX SCIENTIFIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Un thousands, except share and per share data) ‘(Wnaudited) Three Months Ended ‘March 31, March 31, 2012 2011 REVENUES Laboratory services: Drugs-of-abuse testing services S 10578 $ 9,640 Clinical
Slide 9: Summary
2012 Investor Sheet M EDTOX: NASDAQ Symbol: MTOX Summary > Solid positions in large markets relative to our size > Increased revenue diversification > Growth drivers in non-employment related areas > > Opportunity for margin expansion Strong balance sheet and positive cash flow Medtox Sclentine, Ine